{"name":"Sam Chun Dang Pharm. Co. Ltd.","slug":"sam-chun-dang-pharm-co-ltd","ticker":"","exchange":"","domain":"samchundangpharm.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SCD411","genericName":"SCD411","slug":"scd411","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"SCD411","genericName":"SCD411","slug":"scd411","phase":"phase_3","mechanism":"SCD411 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNWGdrc1AwTVllT0E5aVd6Rl9CTEhJdmVUOVBJMXpMTi1YY1NPSEpzdGNrMWsxdWZjSjBwbWdkV1VUdkVzSEcyY3FZN0JRR29WTUxZRU9WdFB3NXJaVjhRRTRzUXV0Wkd5aFNpZDUwZjVZbFNaT01McnVPWUpoQV9fT0hTYkhtX2Zic09TNTd2elM0SV9WblFWekFQbnVCWk9lTmZhU01XWDVFTjRwSkxvNlhrclRnSkFITy03d21rRFNxQW84UHlpUVAtenVfM2tzYzA5TXplYko?oc=5","date":"2026-04-06","type":"pipeline","source":"Korea JoongAng Daily","summary":"Korean oral obesity, insulin stock yo-yos on rumors - Korea JoongAng Daily","headline":"Korean oral obesity, insulin stock yo-yos on rumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQeW82UlRkbGowbFV0eFEyOGRjYW9ESkpjNmVEc1NEaHpVQ3prd0pxSEpndVFzRzNNdEEwT0EzS1hISnR5NE1KMUdGRlVGLWFsUjRfcmFQcUl6TVNOSW14cHdnbk5xOXdxbTBTa1pjVFNzU0V5QXdvN2Nnem1GaFUzZ9IBlAFBVV95cUxOc3FhdEl0TVBNTGJuMFg4ZGhYRGdYV2g1QmZXYVExWnRRVEdwWUZmT1YtODVxWWowUWgzNjJJZVZJc3d0MUlHVGRSSGdudkxoNXZnV0p4bEwzZ3BNaUxzMTBMbk9vSHFDQlFoVnBwNzZwN05MczRiVU0zb2RaYnF2Vnp6NWIxb0lXMl96YnJNV1hmTFo2?oc=5","date":"2026-04-06","type":"pipeline","source":"Chosunbiz","summary":"KOSDAQ active ETFs draw funds, tighten bio stock correlation in South Korea - CHOSUNBIZ - Chosunbiz","headline":"KOSDAQ active ETFs draw funds, tighten bio stock correlation in South Korea - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE4yYU95TXcxNlNsNGhhOExYT2g5TGk5eFJ1M19mOUpVVWM5N0R1TXBEd1AyNHFOQjcxRDRCakh6ZzlPTW5hbXhaNzZzcVplVjJYSFFCUHI5TmRiWVg4RzdINEUtejJFcVNodEU0VzF3?oc=5","date":"2026-04-03","type":"pipeline","source":"KED Global","summary":"Foundayo heats up global weight-loss drug market; Korean drugmakers target sector - KED Global","headline":"Foundayo heats up global weight-loss drug market; Korean drugmakers target sector","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBlcHJIMjk2dHhwX0NkSmd6bWQ0N0NRS0NuQXM2SHJmMTJEWC04M1dMNk5WNzY5ckVCTTVfNXp1SlEzM05PTHdHU2hmMlg3S3lVT05sd2Npb196RGluS09McVdneld4NV9HeEtPeEhn?oc=5","date":"2026-04-01","type":"pipeline","source":"KED Global","summary":"Sam Chun Dang Pharm wipes off $6.6 bn in just 2 days: Three mysteries - KED Global","headline":"Sam Chun Dang Pharm wipes off $6.6 bn in just 2 days: Three mysteries","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOd3hLM2pQbFFKLVNQVmtiNkNFNE5hQ2NVWUgtSU9fVlpSenZfOHB6cjNHRGk2Wk9wXy1sOHgyTlZ1aVdlN0JyQjFGWEtiZ2pTWnFZaTVnVkp5Q1g2OFR3ZXU2MnZtUVhubjU4Z3hkNllyS08wdHp6R0Z5cnRlaFp5V9IBlAFBVV95cUxOYUN6aFlLdWFxVHJjdFlkNUt0Ykx0anA2RHVIelBmQkRMVmhqSENuVVdOUkQ1X1hUYVJkdWpnSlRzSU01clhrQk9EOFZ0Zm9BMkZFOHZYU1kxcHJxRHFZLUU3bmxtT0JPQ0R3UU9BZUl2S2U0bXhNNUtncXVaRnl6UF9VTzRRNVR1U3RBeEZ6UEtYck9y?oc=5","date":"2026-04-01","type":"pipeline","source":"Chosunbiz","summary":"Sam Chun Dang Pharm stokes doubt in Korea as legal threats follow R&D cuts and vague disclosures - CHOSUNBIZ - Chosunbiz","headline":"Sam Chun Dang Pharm stokes doubt in Korea as legal threats follow R&D cuts and vague disclosures - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-27","type":"earnings","source":"simplywall.st","summary":"Sam Chun Dang Pharm (KOSDAQ:000250) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of - simplywall.st","headline":"Sam Chun Dang Pharm (KOSDAQ:000250) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQb2JtZjhsVDQwOVhSSy0zM3duUkg4RW9nYTk3YjFNM0hnQ0tTQVN3dm5tQ1FnT0Q4ZnlGTGZKTVU4QUtBN01VOVowamlYczNhQ1BZUnkxYmZvY3Y2THVhSk9xSHVSTHVtUmNUdm5GaG1JNGdBN19kUjBnQVh1bVFGddIBlAFBVV95cUxQNE1zU0JNTzJJVWg1VS1weTBCZTFSVzVKUF9qckotRmpScDdpSm04Sy1vV1dtOTJfeU1WR25HRUd4eHpwVHBlOTF5TVFfX01hRWtUMnVEQ2JnQkhISGFheVVHWVJEWGFUYjUwRl8zUHBWTjYyVUJaUFotOTNVYjhKLUp1b0tDR08wOFJ1WFE0MV9mUzlu?oc=5","date":"2026-03-05","type":"pipeline","source":"Chosunbiz","summary":"Wegovy hype sends Sam Chun Dang Pharm soaring as governance risks deepen - CHOSUNBIZ - Chosunbiz","headline":"Wegovy hype sends Sam Chun Dang Pharm soaring as governance risks deepen - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjVXdzQ0djliSFp4ZGJLeUQ2aEU4YUgxbEc1YmJaUWc4UFNVbi11RllOMTlIUm10OGs3cXp6cnEyWm1XaURUWHNFWUVYSXhhTTNEelBPdVNNaldZZlFKWUJwRXY0TC1xWTBfRXhXX1BKSjNnaTF1TWc2WkFMNnlRZHFoclp2eUFVQVR5NmJ1NVR0N0J2b2thZHNzOEI5OVlmbkVTaU9GcnE2SVpBalN4TzdQZnI2VlFLVEVFRDBjWkQtaGNCeEVta1NpSm9nQVpGT2J1WkNuRVhqb18xMHVRa1A0R29pTUE?oc=5","date":"2026-01-26","type":"pipeline","source":"Forbes","summary":"Promising New Weight-Loss Pill From South Korea’s Sam Chun Dang Pharm Mints Country’s Newest Billionaire - Forbes","headline":"Promising New Weight-Loss Pill From South Korea’s Sam Chun Dang Pharm Mints Country’s Newest Billionaire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPUE1IcGdlaENWYlF0SWpJdmtRSHEwYkFtWDltUHUwSW53OU8zTVA3TFZMbXo5RHhZbGhVT3MtYVJZbVM5MkJ2dVdHVHhDVVM4NUJNTjRRNktXMDcxd3BQV2lScWtVT2JiMTZQWWJiRXNKaURHM3VEN3hWaHBrQmRyQ2MySmotS2RkY1dPMVhVU2ZfMEc3ZUZGSUV2U2N3R1NlSHFNYw?oc=5","date":"2025-09-23","type":"regulatory","source":"Pearce IP","summary":"Sam Chun Dang’s Biosimilar Aflibercept Approved in Japan and Korea - Pearce IP","headline":"Sam Chun Dang’s Biosimilar Aflibercept Approved in Japan and Korea","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5BZ3Fkd1RYcHpydTVBRi0wTEJVVExiUGZBa2hXb0xsZU52Zkp6bHg3dy1Kajh4RFVaRUs1anh3U1lLWU1MSkRLcHBpOVZzbldYV1M2dndmUmliQllGeTdURmdfQUtyVlZkdkpLalVR0gFyQVVfeXFMT1FnVlVUX1gwSkZZSnJXUXYwMGwwbjVDbzJLRFh0blpfYzRicGlBVmlFTFRwY2RNdU9PZklxZFZEMmRIVWhHQXRqcW93SXptNlJKWElGd2ZoMnNRX2tqeFp2MzhyX0pyWTFfNlZfcElkX2RR?oc=5","date":"2025-07-25","type":"trial","source":"koreabiomed.com","summary":"[Reporter’s Notebook] Sam Chun Dang Pharm’s misleading hype over oral GLP-1 trial data - koreabiomed.com","headline":"[Reporter’s Notebook] Sam Chun Dang Pharm’s misleading hype over oral GLP-1 trial data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOc3A4WVBkb3RFODZfRzN2UjNVcGNaeWZ1d3BxdmZYRFN3WWE4VkY3eUQ2LUUwV0NUWjJTdjN6VHBWTFBld0dYcXlZUjFKTHZ4SUp1SUY4OFA4VXJqZGpDa25RVVJnc0RmOHA5OFNSUWFHcE1reTFwb0MtNjZRMU4tN1ctMUo1VXd3c3BaVmw2M2lhOWMxTnNuNUZ2T0R3NE5ScXRKd2RsYm11Y3pKMDVfSy00c0xIMnljdTV4WFpXaXJkSUdEQVc2NjNXSS0?oc=5","date":"2025-03-13","type":"regulatory","source":"Smartkarma","summary":"Sam Chun Dang Pharm (000250 KS): Oral Semaglutide Trial Begins; Global Expansion of Eylea Biosimilar - Smartkarma","headline":"Sam Chun Dang Pharm (000250 KS): Oral Semaglutide Trial Begins; Global Expansion of Eylea Biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA3anFQWGNpZWdBMTM2MzZFVG12MmdvSExMT1lRSkZ4WmpUR2pETXA3MnVWbzRmWklsSUlab05pNGZyYXNrZ2d0eGJhRWlqVWY5SHZILUdRUWQ1Y1ZxN0Q1SUdkZFR6bUl6Ni1Pb01R0gFyQVVfeXFMTVI3emRZZ3dxbHlvY1V4OGpLTDd4R24wX1RYMC1UMmJxY1llbHhwdjBsTDM3M1dOZmIxWTVXaEhjS1YyV3RNQ1pyQzRoX3RhN3NZcTc4eUtXQmx3cGY3OEpOQkdCYkpHZDRZTXZncmprU2R3?oc=5","date":"2025-01-22","type":"regulatory","source":"koreabiomed.com","summary":"Sam Chun Dang Pharm begins bioequivalence study for oral semaglutide - koreabiomed.com","headline":"Sam Chun Dang Pharm begins bioequivalence study for oral semaglutide","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}